XASXPGC
Market cap510mUSD
Dec 23, Last price
0.50AUD
1D
0.00%
1Q
19.28%
Jan 2017
-38.14%
Name
Paragon Care Ltd
Chart & Performance
Profile
Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.
IPO date
Oct 15, 1999
Employees
400
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 2,969,885 865.41% | 307,630 29.46% | 237,618 0.75% | |||||||
Cost of revenue | 2,923,381 | 338,963 | 270,079 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 46,504 | (31,333) | (32,461) | |||||||
NOPBT Margin | 1.57% | |||||||||
Operating Taxes | 5,672 | 5,198 | 3,311 | |||||||
Tax Rate | 12.20% | |||||||||
NOPAT | 40,832 | (36,531) | (35,772) | |||||||
Net income | 8,381 -22.11% | 10,760 62.19% | 6,634 -19.87% | |||||||
Dividends | (12,613) | (7,886) | (1) | |||||||
Dividend yield | 3.07% | 5.01% | 0.00% | |||||||
Proceeds from repurchase of equity | 406 | (483) | ||||||||
BB yield | -0.26% | 0.26% | ||||||||
Debt | ||||||||||
Debt current | 116,754 | 21,719 | 26,209 | |||||||
Long-term debt | 203,901 | 133,248 | 105,050 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,981 | 2,587 | 33,912 | |||||||
Net debt | 297,081 | 130,197 | 84,795 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 44,452 | 17,749 | 19,032 | |||||||
CAPEX | (6,779) | (21,046) | (4,611) | |||||||
Cash from investing activities | (19,525) | (31,746) | 7,070 | |||||||
Cash from financing activities | (5,953) | (10,002) | (11,930) | |||||||
FCF | 120,382 | (194,577) | (68,371) | |||||||
Balance | ||||||||||
Cash | 19,944 | 22,603 | 46,203 | |||||||
Long term investments | 3,630 | 2,167 | 261 | |||||||
Excess cash | 9,388 | 34,583 | ||||||||
Stockholders' equity | 291,918 | 262,059 | 249,653 | |||||||
Invested Capital | 545,725 | 367,298 | 340,599 | |||||||
ROIC | 8.94% | |||||||||
ROCE | 8.52% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 935,227 | 669,553 | 652,221 | |||||||
Price | 0.44 87.23% | 0.24 -16.07% | 0.28 5.66% | |||||||
Market cap | 411,500 161.53% | 157,345 -13.84% | 182,622 5.66% | |||||||
EV | 708,581 | 296,650 | 273,721 | |||||||
EBITDA | 60,972 | (21,038) | (24,523) | |||||||
EV/EBITDA | 11.62 | |||||||||
Interest | 16,241 | 7,021 | 6,111 | |||||||
Interest/NOPBT | 34.92% |